– USA, OH – Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing invimestrocel for critical care indications, today announced the appointment of Joe Nolan to its Board of Directors, effective January 4, 2023.
“Joe is a strong addition to our Board, bringing more than 30 years of experience managing high-value global pipelines, launching multiple successful drugs and optimizing large-scale commercial operations. His understanding of the equity capital markets and his innovative approach to market access supported the successful launches of several drugs including Zolgensma®, a gene therapy product developed by a company that was acquired by Novartis for $8.7 billion,” said Board chairman, Dr. Ismail Kola.
CEO Dan Camardo added, “I’m delighted to welcome Joe to the Athersys Board. His experience in building high-performance teams, driving operational efficiencies, and launching biopharmaceutical products in competitive markets complement Athersys’ strategy. We look forward to drawing upon his expertise as we advance our corporate strategy and the clinical development of MultiStem®.”
About Joseph Nolan
Joe Nolan is an experienced biotechnology and pharmaceutical executive who currently serves as CEO of Jaguar Gene Therapy, LLC. With this appointment, Athersys has five Directors, four of whom are independent.
Mr. Nolan has particular expertise in launching products that treat central nervous system disorders, most in orphan and specialty settings. Before Jaguar, he was General Manager of AveXis (now Novartis Gene Therapies), where he was a part of the team that launched Zolgensma for the treatment of spinal muscular atrophy, one of two recently approved gene therapies in the U.S. Earlier in his career, Mr. Nolan served as President at Dohmen Life Science Services, CCO at Marathon Pharmaceuticals and CCO at Lundbeck Inc. He has also held senior positions at Takeda Pharmaceuticals and Abbott Laboratories.
“I’m proud to join the Athersys Board and am enthusiastic about MultiStem’s potential across a range of unmet medical needs. My passion is in empowering teams to enhance the quality of care for patients, and in MultiStem, I see a global opportunity that I look forward to helping maximize,” said Joe Nolan.
Mr. Nolan is a Director of Jaguar Gene Therapy and Axovia Therapeutics. He holds a B.S. in Finance from Tulane University and an MBA from the University of Notre Dame.
About Athersys
Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the neurological, inflammatory and immune, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization.
For more, visit www.athersys.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.